 Aimmune Therapeutics Inc NASDAQ:AIMT has been given an average recommendation of Hold by the fourteen ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The average ... 